S V Zaitsev
Imidazoline compounds protect against interleukin 1beta-induced beta-cell apoptosis.
Zaitsev, S V; Appelskog, I B; Kapelioukh, I L; Yang, S N; Köhler, M; Efendic, S; Berggren, P O; Maarabouni, M
Authors
I B Appelskog
I L Kapelioukh
S N Yang
M Köhler
S Efendic
P O Berggren
DR Mirna Maarabouni m.m.maarabouni@keele.ac.uk
Contributors
DR Mirna Maarabouni m.m.maarabouni@keele.ac.uk
Researcher
Abstract
Imidazoline compounds have been considered for the treatment of type 2 diabetes. We have now investigated the effects of imidazolines on interleukin (IL)-1beta-induced beta-cell apoptosis and the signal transduction pathways involved. Inhibition of Ca2+ influx into beta-cells by D-600, a blocker of voltage-gated L-type Ca2+ channels, suppressed IL-1beta-induced apoptosis. Our data show that calcineurin, Ca2+/calmodulin-dependent serine/threonine protein phosphatase 2B, is responsible for the effect of Ca2+ on beta-cell apoptosis. We also demonstrate that IL-1beta-mediated apoptosis correlates with expression of inducible nitric oxide synthase (iNOS) and the increase in intracellular production of nitric oxide. An inhibitor of cGMP-dependent protein kinase (PKG), KT5823, suppressed IL-1beta-induced apoptosis, suggesting the involvement of a PKG-dependent pathway in the apoptotic process. One of the major findings in this study is that imidazoline compounds RX871024 and efaroxan, suggested as prototypes of a new generation of drugs against type 2 diabetes, can protect against IL-1beta-induced apoptosis in pancreatic beta-cells, possibly by their inhibition of the expression of iNOS, a key element in the IL-1beta-induced apoptotic pathway in pancreatic beta-cells. These data suggest that imidazoline compounds should be explored as a potential therapeutic agent for the treatment of both type 1 and type 2 diabetes.
Citation
Zaitsev, S. V., Appelskog, I. B., Kapelioukh, I. L., Yang, S. N., Köhler, M., Efendic, S., …Maarabouni, M. (2001). Imidazoline compounds protect against interleukin 1beta-induced beta-cell apoptosis. Diabetes, 50(suppl_1), Article S70. https://doi.org/10.2337/diabetes.50.2007.s70
Journal Article Type | Article |
---|---|
Publication Date | Feb 1, 2001 |
Deposit Date | May 15, 2024 |
Journal | Diabetes |
Print ISSN | 0012-1797 |
Electronic ISSN | 1939-327X |
Publisher | American Diabetes Association |
Peer Reviewed | Peer Reviewed |
Volume | 50 |
Issue | suppl_1 |
Article Number | S70 |
DOI | https://doi.org/10.2337/diabetes.50.2007.s70 |
Public URL | https://keele-repository.worktribe.com/output/828274 |
Publisher URL | https://diabetesjournals.org/diabetes/article/50/suppl_1/S70/11667/Imidazoline-compounds-protect-against-interleukin?searchresult=1 |
You might also like
Investigation into the Role of Long-Non-Coding RNA MIAT in Leukemia
(2023)
Journal Article
Downloadable Citations
About Keele Repository
Administrator e-mail: research.openaccess@keele.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search